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Summary of the recent Nature Biotechnology article on  
“Transparency Tools in Gene Patenting for informing policy and practice.”
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As the global intellectual property (IP) system grows and now impacts virtually all 
citizens, it is crucial that the means to understand these rights and their teachings, 
as well as their implications and scope become global public goods. To do so re-
quires not only that the primary data is available freely and openly in a standardized 
and re-useable form, but that tools to visualize, analyse and model that data are 
similarly open and free public goods, adaptable to diverse needs and uses; this we 
call ‘transparency’.
Open web-based platforms that enable the aggregation, commentary and mapping 
of this knowledge by the community and that transcend any one jurisdiction or field 
of innovation, are also needed. 
These imperatives have informed Cambia’s development of The Lens (an open ac-
cess, autonomous web-based patent search facility), and in particular, its biological 
innovation capability, part of which is referred to here as the PatSeq facility (see box).
Gene patents are among the most contentious, opaque and poorly understood as-
pects of modern IP. Inventions and products or services that hinge on knowledge of 
or direct use of the sequences that make up genetic material, typically DNA, or the 
proteins that genes encode, are becoming common and very important. Societal 
concerns about the appropriateness of allowing patenting of these components of 
living systems have also become prominent.
Transparency in relation to the extent and scope of genetic inventions is critical, and 
has several important roles. First, transparency allows examiners to understand the 
invention and to determine if it meets patentability requirements. Second, it enables 
public access to, and use of, the invention concept to enact the patent ‘bargain’ or 
‘compact’, thereby fostering follow-on inventions, cumulative innovation, and reducing 
duplication of effort. Third, transparency gives policy-makers an evidence base and 
context to ensure that patent practice is aligned with the economic and social goals 
of the IP system. In each of these critical roles, patent office practice in relation to 
gene patenting falls short. 
DNA and protein sequences are made up of either combinations of four letters – 
A, C, G, and T, in the case of DNA – or 20 types of amino acids, each with different 
chemical properties – in the case of protein. To understand their structure, function 
and similarity, they must be read using specialized computer software tools. Therefore, 
when disclosed in a patent document, an examiner or practitioner would need to use 
computer-mediated searching, analysis and visual tools to interpret their contextual 
value or meaning. Any form used in the patenting process that does not facilitate 
access to computer searchable information – often called ‘machine readable’ – 
in our view fails to meet the patent system’s public disclosure requirements.
In a recent publication (www.nature.com/nbt/journal/v31/n12/full/nbt.2755.html) we 
reported the development and availability of an open, public, web-based platform 
that has great potential to improve the transparency of gene patenting worldwide. 
Our international survey of 55 patent offices during the period July to October 2011 
which focused on standards and practices regarding patentability of genetic se-
quences, revealed significant room for improvement in terms of making these data 
freely and publicly available for aggregation. While patentability requirements appear 
to be converging in at least 35 respondent patent offices, public disclosure of patent 
sequences remains restricted to visual inspection. Open public capabilities to search 
and analyse sequence-based discoveries and inventions are almost non-existent. 
Cambia’s international survey of 55 patent 
offices, which focused on standards and 
practices regarding patentability of genetic 
sequences, revealed significant room for 
improvement in terms of making these data 
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The PatSeq Toolkit
In the multilingual Lens facility, we developed a suite of tools to navigate patent and sequence information. 
For example, when a patent document contains a sequence disclosure, a small helical DNA structure 
appears in the information column of the search results page alerting users to its availability. We have 
also introduced a sequence tab that clarifies the nature of the disclosed sequence(s) within the document 
portfolio allowing users to search and filter the metadata (nature of sequence, length, origin of organism), 
whenever available, to locate the sequence within the document, and to view the original data source 
(where we downloaded the sequence from). We also created PatSeq Explorer, PatSeq Analyzer, and PatSeq 
Finder for more in-depth analyses.
PatSeq Explorer enables multi-level visualization and navigation of patent disclosed sequences that map 
according to various homology thresholds to a reference genome, the first publicly available example of 
which is the human genome. At the genome and chromosome levels, users can investigate overall patenting 
trends, filter, and search sequence and patent attributes, and link to various sets of patent documents in 
The Lens database or choose to investigate further and analyze the sequence at the locus and gene levels 
(see Fig. 1). Mapped sequence entries are displayed according to their location in the patent document and 
their type, along with a summary panel view of their numbers and their corresponding patent documents 
counts in the jurisdictions in which the sequences were disclosed. All views are embeddable in blogs and 
social network facilities (to encourage uptake of evidence-based tools) and we expect all documents and 
sequence collections to be downloadable in the near future.
PatSeq Analyzer: enables users to zoom in to the details of a particular sequence entry, view and 
compare disclosed sequence ID numbers within and across various patent documents and analyze their 
corresponding patent attributes within a specific gene area. The tool is a modified genome viewer built and 
integrated into PatSeq Explorer based on the open source HTML5/SVG genome maps browser developed 
by the Computational Medicine Institute, Prince Felipe Research Centre, Valencia, Spain. All views in 
PatSeq Analyzer are also embeddable.
PatSeq Finder enables users to query their own sequence against the PatSeq databases and conduct 
sequence similarity searches. Results from such searches are aligned based on a score of relatedness to the 
original query sequence and display information relating to corresponding patent documents. Users can 
view sequences referenced in the claims, read the corresponding patent claims, examine alignment details, 
sequence annotation, and embed or download results in various formats.
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To address this gap, Cambia has expanded the publicly search-
able patent sequence database in The Lens (www.lens.org) to 
include data from 15 jurisdictions and has developed a suite of 
new patent sequence (PatSeq) tools to enable exploration of 
the legal and scientific information within biological patents as 
they relate to a particular genome. The first exploratory tools 
target gene patents and their disclosed biological sequences 
associated with the human genome, and provide a platform to 
map, analyse, annotate and share this knowledge with anyone.
Although the recent decision by the US Supreme Court on 
breast cancer genes (Association for Molecular Patholo-
gy (AMP) v Myriad Genetics) held that naturally occurring 
sequences are not patentable in the US (see www.wipo.
int/wipo_magazine/en/2013/04/article_0007.html), isolated 
genomic sequences are still patentable in many jurisdictions, 
including in Australia, Canada, Europe and Japan (for an exam-
ple of a gene patent, check claims 1-3 in the Australian patent 
AU_686004_B2 at www.lens.org/lens/patent/AU_686004_B2). 
As markets and innovation become increasingly globalized, 
such differences in national patent practice and policy un-
derline the need for improved, standardized and open data 
sets, and improved compliance standards, as well as shared, 
open, decision-making tools to support the development of a 
favorable policy environment for biological innovation. 
The Myriad case also highlighted the technical complexity of 
genomic sequence-based discoveries and inventions and the 
urgent need for more precise tools that identify similarities in 
the sequences disclosed in patents, especially in the claims 
section of a patent. 
In gene patenting, there is a critical difference between dis-
closure of sequences and claiming of sequences. Upon 
submitting a patent application for a biological invention, the 
applicant is required to disclose all involved sequences (those 
that are simply used as references in the document, those that 
support the invention, or those that constitute the invention), 
in a separate section, called sequence listings section. When 
all these sequences are disclosed, it is critical to have tools 
that distinguish and illuminate the role, function, and location 
of each disclosed sequence vis-à-vis the invention, as well as 
its similarity to all previously disclosed sequences. Without 
such technical knowledge and clarifying tools, the public, many 
policy-makers, innovators and investors are often confused 
about the extent and scope of gene patents. 
In general, we found that many sequences are disclosed but 
few are claimed as genes. If a sequence per se is claimed, it is 
usually claimed as an isolated or purified molecule in a particular 
jurisdiction. A claimed gene sequence means that any potential 
use of that sequence is restricted and will need to be licensed 
from the patent holder for the duration of the patent term or for 
as long as the patent is active in that jurisdiction. However, if the 
sequence is claimed as part of a larger sequence or as a target 
for a specific method, the uses of that particular sequence are 
unlikely to be exclusive making it possible for other inventors to 
access and use it freely without the need to negotiate a license. 
The public and innovators must be able to readily distinguish 
these cases to better understand the extent and scope of 
granted rights on gene sequences, reduce investment risks, 
and stimulate an equitable and inclusive innovation system, 
but this is extremely difficult. 
While major patent offices claim to have sophisticated da-
tabases available to them that comprise a substantial set of 
sequences, in general the public cannot access or use these 
tools. Moreover, many patent offices with limited budgets or 
serving jurisdictions with emerging IP systems do not have 
access to such tools. 
Even informal collaborations that seek to harmonize patent 
sequence disclosure and availability between countries are 
limited in scope. For example, the collaboration between 
the DNA Databank of Japan (DDBJ) (www.ddbj.nig.ac.jp/ ); 
the European Nucleotide Archives (ENA) (www.ebi.ac.uk/
ena); and the GenBank-PAT division at the National Center 
for Biotechnology Information (NCBI) (www.ncbi.nlm.nih.gov/
genbank/) in the US, is limited to sharing nucleotide-based 
patent sequences with no formal agreement, as yet, to share 
protein-based patent sequences. The International Nucleotide 
Sequence Database Collaboration (INSDC) (www.insdc.org), 
which brings these three major public databases together, fos-
ters the exchange of nucleotide-based patent sequences on a 
daily basis. While each database may have duplicate sequence 
listings from PCT applications and granted US patents, they 
each maintain a slightly different record of patent sequences. 
While some commercial vendors claim to offer comprehensive 
data and sophisticated analysis, this is an expensive means 
of accessing public information. And even these commercial 
databases are incomplete. 
PATENT-DISCLOSED SEQUENCES  
AND THE HUMAN GENOME
Cambia’s biological facility within The Lens (www.lens.org/lens/
biological_search) provides an evidence-based understanding 
of the complex gene patenting landscape. It allows sequence 
and patent data aggregation, analysis and visualization, and 
is equipped with tools to dynamically search and find patent 
sequences associated with several genomes with various 
degrees of similarity, and to compare the scope of patenting, 
beginning with the human genome. Our analysis of the scope 
of patenting of known genes on the human genome showed 
that the percentage of known genes referenced – mentioned 
in the claims section of the patent but not necessarily claimed 
– ranges from 26 percent to 62 percent. 
→
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Fig. 1. In PatSeq Explorer, users can view the whole genome or any individual chromosome (Chromosome 17 of the human genome is depicted 
above), scan information about genes or disorders and traits at a particular location (in this example position 40-50 Mb is highlighted) using data 
from other public databases, and view patent sequence profiles at exact gene positions. Here, we show where one of the breast cancer gene, BRCA1, 
is located using PatSeq Analyzer. Users can then analyze patent attributes for a particular aligned patent sequence under the gene of interest.
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By August 2012, we had 131,339 nucleotide and 15,054 ami-
no acid sequence listing entries mapped with 100 percent 
homology onto the human genome. These were referenced 
in the claims of 13,985 US issued patents. 
CLAIMED VERSUS DISCLOSED  
NUCLEOTIDE SEQUENCES 
After optimizing and extending the algorithms to select pat-
ent documents that reference a sequence in their claims, we 
began analyzing manually the claims associated with only 
the fully aligned 131,339 nucleotide-sequence entries (not the 
amino acid sequence entries). These were referenced in 2,716 
patents. We found that 76,910 sequences out of the 131,339 
sequences mapped uniquely with 100 percent homology to 
the human genome and corresponded to 2,685 patents. The 
remaining 54,429 sequences were repeated in duplicated 
patent documents. According to the Myriad decision, the fully 
aligned sequences would be considered natural nucleotide 
sequences from the human genome, and therefore non-pat-
entable in an unmodified form.
An analysis of the claims referencing these unique sequences 
revealed a variety of strategies for claiming a nucleotide se-
quence; that a small proportion (13 percent) of these sequenc-
es are claimed as sequence composition (having exclusive 
rights on the use of that sequence); and that about a third of 
the corresponding patents were not maintained for their full 
potential lifetime (i.e. 20 years). Further analysis of the claimed 
and patented nucleotide sequences suggested that the public 
and private institutes have different perceptions of the value of 
gene patents and the models for their use.
PATENT OFFICE SURVEY RESULTS
Almost all respondent patent offices indicated that they comply 
with the agreed standard for disclosure of sequences associat-
ed with patent filings (the ST.25 standard), which unfortunately, 
does not stipulate machine-readability. Most offices – with the 
exception of Israel – make sequence listings publicly available. 
However, they are available mostly as part of the published 
patent document, in pdf or image formats, and thus not ma-
chine-readable. A few patent offices, such as those of Canada, 
Germany, and Hungary provide machine-searchable sequence 
listings on their websites, whereas Japan, the EPO, and the 
US, as well as the Republic of Korea to some extent, provide 
machine-searchable sequence listings through third party 
providers or electronic downloadable files via their websites. 
These are often fee-based.
While the survey generated a more realistic picture of the total 
count of sequence listings from some jurisdictions, this proved 
difficult for many others, especially those that rely on regional 
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patent offices, such as the EPO, and WIPO, for that information, 
or those that do not disclose publicly the yearly counts of such 
sequence listings. For example, in the US, where compliance 
with sequence rules is more rigorously observed, we found 
several thousand sequence listings cited in patents published 
since 1990 that were not included in the GenBank–PAT divi-
sion database.
Our survey confirmed the lack of transparent public tools to 
navigate gene patents. While the Myriad decision has clarified, 
to some extent, the US position on gene sequence claiming, 
the ruling also exposed the critical need for, and lack of, nu-
anced and precise analysis of gene patents at both national 
and global level. Without transparency tools, the public will be 
disadvantaged, uncertainty will continue, compromising entre-
preneurialism and investment, and inefficient use of resources 
will persist in industry and public sector innovation, to the det-
riment of informed policy making. Cambia’s biological facility 
within The Lens offers an open public platform that serves as a 
uniquely valuable alternative to the current commercial services 
that serve only a few elite innovators in biological sciences.
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